ACHV Key Statistics, Chart & Performance
The current stock price of ACHV is 4.8 USD. In the past month the price decreased by -3.04%. In the past year, price increased by 5.75%.
ACHV Latest News, Press Relases and Analysis
ACHV Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.21 | 404.37B | ||
| AMGN | AMGEN INC | 15.55 | 183.14B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 151.29B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.43 | 116.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.13 | 76.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 921.25 | 62.07B | ||
| INSM | INSMED INC | N/A | 43.75B | ||
| NTRA | NATERA INC | N/A | 33.38B | ||
| BIIB | BIOGEN INC | 10.86 | 26.67B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.32 | 20.82B | ||
| INCY | INCYTE CORP | 15.38 | 19.38B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.19B |
Related stock screener links
About ACHV
Company Profile
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 25 full-time employees. The firm focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
Company Info
ACHIEVE LIFE SCIENCES INC
22722 29Th Dr. Se, Suite 100
Seattle WASHINGTON V6E 4H1 US
CEO: John Bencich
Employees: 25
Phone: 14256861500
ACHIEVE LIFE SCIENCES INC / ACHV FAQ
What does ACHV do?
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 25 full-time employees. The firm focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. The company has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence.
What is the current price of ACHV stock?
The current stock price of ACHV is 4.8 USD. The price increased by 0.42% in the last trading session.
Does ACHV stock pay dividends?
ACHV does not pay a dividend.
What is the ChartMill technical and fundamental rating of ACHV stock?
ACHV has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the short interest for ACHV stock?
The outstanding short interest for ACHIEVE LIFE SCIENCES INC (ACHV) is 12.48% of its float.
ACHV Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ACHV. When comparing the yearly performance of all stocks, ACHV is one of the better performing stocks in the market, outperforming 90.89% of all stocks.
ACHV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ACHV. ACHV may be in some trouble as it scores bad on both profitability and health.
ACHV Financial Highlights
Over the last trailing twelve months ACHV reported a non-GAAP Earnings per Share(EPS) of -1.38. The EPS decreased by -22.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -100.59% | ||
| ROE | -155.72% | ||
| Debt/Equity | 0.26 |
ACHV Forecast & Estimates
13 analysts have analysed ACHV and the average price target is 15.81 USD. This implies a price increase of 229.38% is expected in the next year compared to the current price of 4.8.